Catalent Acquires MaSTherCell Global from Great Point Partners and Co-investors
February 3, 2020
Catalent Pharma Solutions has signed a definitive agreement to acquire MaSTherCell Global, a cell and gene therapy CDMO that Great Point Partners had invested in alongside Orgenesis and SFPI-FPIM. MaSTherCell, headquartered in Gosselies, Belgium with a U.S. facility in Houston, Texas, expands Catalent's cell and gene therapy development and manufacturing capabilities and adds significant European and U.S. capacity.
- Targets
- MaSTherCell Global
- Sellers
- Great Point Partners, Orgenesis, SFPI-FPIM
- Industry
- Biotechnology
- Location
- Hainaut, Belgium
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
GI Partners Completes Acquisition of Charles River’s CDMO and Cell Solutions Businesses, Forms Rose BioSolutions
May 8, 2026
Healthcare Services
GI Partners completed its acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories, creating an independent advanced therapy manufacturing company, Rose BioSolutions. Rose BioSolutions will provide end-to-end cell and gene therapy development and manufacturing, covering plasmid DNA, viral vectors, cell therapy production, and cellular starting materials.
-
HealthQuest Capital and Great Point Partners Invest Growth Equity in Cellipont Bioservices; Darren Head Named CEO
October 7, 2024
Biotechnology
Cellipont Bioservices named Darren Head as CEO and announced a minority growth equity investment from HealthQuest Capital, with majority investor Great Point Partners also participating. The capital and leadership transition are intended to support Cellipont’s expansion of cell-therapy CDMO capabilities and operational growth.
-
Great Point Partners Makes Growth Investment in iXCells Biotechnologies
September 29, 2022
Biotechnology
Great Point Partners, a Greenwich, CT-based healthcare-focused private investment firm, has made a growth investment in San Diego-based iXCells Biotechnologies. The capital will be used to expand iXCells' operational capacity, broaden its product and service offering (including bioanalytical capabilities) and support growth into adjacent high-growth end markets such as personalized medicine and rare disease research.
-
Galapagos NV Acquires CellPoint and AboundBio
June 21, 2022
Biotechnology
Galapagos NV has acquired CellPoint and AboundBio to accelerate access to next-generation cell therapies, combining CellPoint's decentralized point-of-care CAR-T manufacturing platform with AboundBio's fully human antibody discovery capabilities. The deal includes an upfront €125 million for CellPoint (plus up to €100 million in milestones) and $14 million for AboundBio, positioning Galapagos to expand its cell therapy pipeline and validate a rapid vein-to-vein delivery model.
-
Catalent Acquires Delphi Genetics to Add Plasmid DNA Capabilities
February 23, 2021
Biotechnology
Catalent has agreed to acquire 100% of Delphi Genetics, a Belgium-based plasmid DNA (pDNA) CDMO, and will integrate Delphi's pDNA development and cGMP manufacturing capabilities into its Cell & Gene Therapy business. The deal also supports Catalent's launch of pDNA services at its Rockville, Maryland facility, expanding integrated pDNA supply across Europe and the U.S.
-
Lonza AG Acquires PharmaCell BV
June 1, 2017
Biotechnology
Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.